Johanna C Bendell Selected Research

Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)

11/2020	Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study.
1/2020	The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC).
1/2019	Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors.
1/2017	A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.
8/2014	Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
2/2011	A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).
8/2007	Targeted therapy in rectal cancer.
6/2007	Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Johanna C Bendell Research Topics

Disease

84	Neoplasms (Cancer) 11/2022 - 06/2003
38	Colorectal Neoplasms (Colorectal Cancer) 11/2022 - 02/2006
12	Disease Progression 01/2021 - 11/2011
12	Adenocarcinoma 10/2020 - 03/2007
10	Fatigue 03/2022 - 01/2013
8	Nausea 03/2022 - 01/2013
8	Neutropenia 01/2021 - 09/2012
7	Neoplasm Metastasis (Metastasis) 01/2021 - 06/2003
7	Thrombocytopenia (Thrombopenia) 01/2019 - 07/2012
7	Rectal Neoplasms (Rectal Cancer) 09/2017 - 02/2006
6	Diarrhea 01/2022 - 12/2013
6	Pancreatic Neoplasms (Pancreatic Cancer) 01/2019 - 05/2007
5	Exanthema (Rash) 03/2022 - 02/2011
5	Anemia 01/2022 - 01/2014
5	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 01/2016
5	Carcinoma (Carcinomatosis) 04/2013 - 05/2005
4	Hypertension (High Blood Pressure) 01/2021 - 07/2017
4	Edema (Dropsy) 01/2020 - 01/2014
4	Mucositis 02/2015 - 02/2011
4	Esophageal Neoplasms (Esophageal Cancer) 07/2012 - 03/2007
3	Prostatic Neoplasms (Prostate Cancer) 11/2022 - 01/2019
3	Ovarian Neoplasms (Ovarian Cancer) 11/2020 - 03/2016
3	Asthenia 01/2019 - 01/2013
3	Vomiting 01/2019 - 04/2013
3	Wounds and Injuries (Trauma) 01/2019 - 06/2013
3	Febrile Neutropenia 08/2013 - 03/2008
3	Pathologic Complete Response 03/2008 - 03/2007
2	Brain Neoplasms (Brain Tumor) 01/2022 - 06/2003
2	Stomach Neoplasms (Stomach Cancer) 11/2021 - 01/2020
2	Colonic Neoplasms (Colon Cancer) 10/2021 - 01/2021
2	Stomatitis 01/2019 - 01/2015
2	Inflammation (Inflammations) 12/2015 - 04/2003
2	Melanoma (Melanoma, Malignant) 12/2015 - 08/2012
2	Uveitis 02/2015 - 06/2013
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 03/2008 - 03/2007
2	Anus Neoplasms (Anal Cancer) 05/2007 - 04/2003
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2022

Drug/Important Bio-Agent (IBA)

29	Bevacizumab (Avastin)FDA Link 04/2022 - 06/2007
15	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021 - 06/2007
13	Fluorouracil (Carac)FDA LinkGeneric 10/2021 - 04/2003
11	Irinotecan (Camptosar)FDA LinkGeneric 07/2016 - 08/2007
11	Capecitabine (Xeloda)FDA Link 12/2015 - 02/2006
9	Biomarkers (Surrogate Marker)IBA 11/2021 - 06/2013
9	Cetuximab (Erbitux)FDA Link 01/2021 - 08/2007
8	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2020 - 06/2007
6	Everolimus FDA Link 01/2022 - 01/2011
6	Panitumumab (Vectibix)FDA Link 01/2021 - 01/2011
6	Gemcitabine FDA Link 01/2019 - 01/2011
5	trifluridine tipiracil drug combinationIBA 01/2021 - 11/2015
5	Monoclonal AntibodiesIBA 01/2020 - 04/2013
5	Carboplatin (JM8)FDA LinkGeneric 01/2018 - 03/2007
5	Paclitaxel (Taxol)FDA LinkGeneric 09/2012 - 03/2007
4	Phosphotransferases (Kinase)IBA 01/2022 - 10/2015
4	Leucovorin (Folinic Acid)FDA Link 01/2021 - 03/2008
4	trametinibIBA 01/2020 - 08/2012
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2020 - 08/2012
3	Circulating Tumor DNAIBA 04/2022 - 01/2020
3	NivolumabIBA 03/2022 - 01/2021
3	Transaminases (Aminotransferases)IBA 01/2022 - 06/2013
3	pembrolizumabIBA 11/2021 - 01/2020
3	prexasertibIBA 01/2021 - 01/2020
3	dabrafenibIBA 01/2020 - 12/2015
3	130-nm albumin-bound paclitaxelIBA 01/2019 - 12/2017
3	Messenger RNA (mRNA)IBA 12/2017 - 01/2013
3	ErbB Receptors (EGF Receptor)IBA 03/2016 - 02/2006
2	durvalumabIBA 11/2022 - 01/2020
2	SteamIBA 04/2022 - 01/2020
2	LY3023414IBA 01/2022 - 01/2018
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 11/2021 - 10/2020
2	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 11/2007
2	Pemetrexed (MTA)FDA Link 01/2021 - 08/2013
2	atezolizumabIBA 11/2020 - 01/2016
2	RamucirumabIBA 10/2020 - 01/2019
2	Differentiation AntigensIBA 01/2020 - 08/2014
2	Trastuzumab (Herceptin)FDA Link 01/2020 - 06/2003
2	regorafenibIBA 01/2019 - 10/2015
2	ME-344IBA 10/2017 - 04/2015
2	Axitinib (AG 013736)IBA 07/2017 - 12/2013
2	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2017 - 09/2013
2	onartuzumabIBA 01/2017 - 09/2013
2	5- (2,4- dihydroxy- 5- isopropylphenyl)- 4- (4- morpholin- 4- ylmethylphenyl)isoxazole- 3- carboxylic acid ethylamideIBA 07/2016 - 01/2015
2	TOR Serine-Threonine KinasesIBA 01/2016 - 10/2015
2	AntigensIBA 01/2016 - 01/2009
2	KRN-330IBA 08/2014 - 04/2013
2	NVP-BKM120IBA 08/2014 - 01/2012
2	Angiogenesis InhibitorsIBA 08/2013 - 08/2007
2	PanobinostatIBA 09/2012 - 03/2011
2	Dihydrotachysterol (AT 10)IBA 07/2012 - 09/2011
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 07/2012 - 02/2011
1	Prostate-Specific Antigen (Semenogelase)IBA 11/2022
1	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 11/2022

Therapy/Procedure

33	Therapeutics 03/2022 - 06/2003
28	Drug Therapy (Chemotherapy) 01/2021 - 04/2003
14	Radiotherapy 01/2019 - 04/2003
5	Neoadjuvant Therapy 10/2017 - 08/2007
3	Castration 11/2022 - 01/2019
3	Chemoradiotherapy 01/2009 - 11/2007
2	Adjuvant Chemotherapy 01/2021 - 06/2007
2	Esophagectomy 03/2008 - 03/2007
2	Proctectomy 05/2007 - 04/2003